Enzymatica AB (publ)

Stockholm Stock Exchange ENZY.ST

Enzymatica AB (publ) Total Non-Current Liabilities for the year ending December 31, 2023: USD 1.66 M

Enzymatica AB (publ) Total Non-Current Liabilities is USD 1.66 M for the year ending December 31, 2023, a -17.50% change year over year. Total non-current liabilities are the sum of long-term debt and other non-current liabilities.

Enzymatica AB (publ) Total Non-Current Liabilities for the year ending December 31, 2022 was USD 2.02 M, a 1,528.39% change year over year.
Enzymatica AB (publ) Total Non-Current Liabilities for the year ending December 31, 2021 was USD 123.86 K, a -51.01% change year over year.
Enzymatica AB (publ) Total Non-Current Liabilities for the year ending December 31, 2020 was USD 252.82 K, a -38.44% change year over year.
Enzymatica AB (publ) Total Non-Current Liabilities for the year ending December 31, 2019 was USD 410.70 K, a -5.74% change year over year.

Key data

Date	Total Non-Current Liabilities	Shareholders' Equity	Other Liabilities	Total Liabilities

Stockholm Stock Exchange: ENZY.ST

Enzymatica AB (publ)

CEO	Mr. Claus Egstrand
IPO Date	June 14, 2011
Location	Sweden
Headquarters	Ideon Science Park
Employees	17
Sector	Healthcare
Industries Biotechnology Cleaning Supplies Dental Care Non-Alcoholic Beverages Personal Care Pharmaceuticals Plastics Vaccines

Description

Enzymatica AB, a life science company, develops and sells medical devices for infection-related diseases. The company's product includes ColdZyme mouth spray, which prevents common cold and reduces the duration of illness. It also provides enzyme formulations. The company sells mouth spray under the ViruProtect brand in Denmark; STADAProtect brand in Germany; Psysiomer Stop Virus brand in France; and Zerinol Virus Defense brand in Italy. Enzymatica AB was incorporated in 2007 and is headquartered in Lund, Sweden.

Key trends

Past 5 years